Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Rising breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously immunized individuals have raised concerns for the need for a booster vaccine dose to combat waning antibody levels and new variants. Here we report the results of the open-label, non-randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Laurence, Vrbicky, Keith, Montefiori, David, Huang, Wenmei, Nestorova, Biliana, Chang, Ying, Carfi, Andrea, Edwards, Darin K., Oestreicher, Judy, Legault, Holly, Dutko, Frank J., Girard, Bethany, Pajon, Rolando, Miller, Jacqueline M., Das, Rituparna, Leav, Brett, McPhee, Roderick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117133/
https://www.ncbi.nlm.nih.gov/pubmed/35241844
http://dx.doi.org/10.1038/s41591-022-01739-w

Ejemplares similares

Ejemplares similares